In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oncternal Therapeutics (ONCT - Research Report), with a price target of $7.00. The company's shares closed yesterday at $1.00.Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Equillium. According to TipRanks, Selvaraju has an average return of -31.2% and a 19.75% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncternal Therapeutics with a $7.50 average price target.
https://www.tipranks.com/news/blurbs/oncternal-therapeutics-onct-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Oncternal Therapeutics Charts.
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Oncternal Therapeutics Charts.